Illustration of time at risk of IMD, MCV4 vaccination uptake and
![Illustration of time at risk of IMD, MCV4 vaccination uptake and](https://www.researchgate.net/profile/Dominique-Caugant/publication/349613179/figure/fig1/AS:1000535532511232@1615557668515/Illustration-of-time-at-risk-of-IMD-MCV4-vaccination-uptake-and-duration-of-protection.png)
Download scientific diagram | Illustration of time at risk of IMD, MCV4 vaccination uptake and duration of protection from MCV4 in all cohorts studied. IMD = Invasive meningococcal disease, MCV4 = meningococcal ACWY conjugate vaccine from publication: Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine | In Norway, the incidence of invasive meningococcal disease (IMD) is higher among 16–19-year-olds than in the general population. Most IMD cases among teenagers are caused by serogroup Y. Since 2011, one dose of meningococcal ACWY conjugate vaccine (MCV4) has been recommended | Meningococcal Vaccines, Conjugate Vaccines and Vaccines | ResearchGate, the professional network for scientists.
![](https://www.researchgate.net/profile/Dominique-Caugant/publication/349613179/figure/fig4/AS:1000535532527620@1615557668634/Cost-effectiveness-acceptability-curve-comparing-the-strategy-Universal-15-yellow-line_Q320.jpg)
Illustration of time at risk of IMD, MCV4 vaccination uptake and
![](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20200417064852078-0023:S0950268820000734:S0950268820000734_fig3.png?pub-status=live)
Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors, Epidemiology & Infection
![](https://ars.els-cdn.com/content/image/1-s2.0-S0264410X15011457-gr2.jpg)
Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment - ScienceDirect
![](https://www.grandviewresearch.com/static/img/research/us-meningococcal-vaccines-market.png)
Meningococcal Vaccines Market Size & Share Report, 2030
![](https://europepmc.org/articles/PMC5989912/bin/khvi-14-05-1458175-g002.jpg)
Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. - Abstract - Europe PMC
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40121-021-00499-3/MediaObjects/40121_2021_499_Fig4_HTML.png)
Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination
![](https://www.tandfonline.com/cms/asset/a4b9767c-2b30-4275-ab83-5d22d3baa2f1/khvi_a_10922302_f0001.gif)
Full article: The changing epidemiology of meningococcal disease in North America 1945–2010
![](https://patentimages.storage.googleapis.com/30/ee/08/a8973c02a92c23/imgf000127_0001.png)
WO2018142280A2 - Neisseria meningitidis compositions and methods thereof - Google Patents
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41390-023-02478-5/MediaObjects/41390_2023_2478_Fig3_HTML.png)
Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study
![](https://patentimages.storage.googleapis.com/17/77/b5/8e92882dbff3f5/imgf000093_0001.png)
WO2016132294A1 - Neisseria meningitidis compositions and methods thereof - Google Patents
![](https://www.scielosp.org/media/assets/rpsp/v41/1020-4989-rpsp-41-e158-gf01.jpg)
SciELO - Saúde Pública - Impact and effectiveness of meningococcal vaccines: a review Impact and effectiveness of meningococcal vaccines: a review
![](https://www.researchgate.net/profile/Dominique-Caugant/publication/349613179/figure/fig1/AS:1000535532511232@1615557668515/Illustration-of-time-at-risk-of-IMD-MCV4-vaccination-uptake-and-duration-of-protection.png)
Illustration of time at risk of IMD, MCV4 vaccination uptake and
![](https://ars.els-cdn.com/content/image/1-s2.0-S1198743X2200338X-gr2.jpg)
Immunogenicity and safety of the meningococcal B recombinant (4CMenB) vaccine in allogeneic hematopoietic cell transplantation recipients - ScienceDirect
![](https://www.canada.ca/content/dam/phac-aspc/images/services/publications/vaccines-immunization/bivalent-factor-h-binding-protein-meningococcal-serogroup-b-prevention-meningococcal-b-disease/figure-4-eng.jpg)
The Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease